🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France

Recruitingn/aAges any - anyAllCentre Hospitalier Universitaire de Nīmes
NCT02938611 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * chronic kidney disease (stage \>= 4) Exclusion Criteria: \-
💊

What it tests

  • Not listed
📍

Where

4 sites
AIDER - Unité de Dialyse d'Alès
Alès, France
AIDER - Unité de Dialyse de Nîmes, CHU Carémeau
Nîmes, France
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, France
Gardialyse
Nîmes, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy